289 related articles for article (PubMed ID: 30045682)
1. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
5. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
[TBL] [Abstract][Full Text] [Related]
6. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
7. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib: first global approval.
Cameron F; Sanford M
Drugs; 2014 Feb; 74(2):263-71. PubMed ID: 24464309
[TBL] [Abstract][Full Text] [Related]
10. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
12. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
Muñoz J; Sarosiek S; Castillo JJ
Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
[TBL] [Abstract][Full Text] [Related]
13. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
14. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
[TBL] [Abstract][Full Text] [Related]
16. Targets for Ibrutinib Beyond B Cell Malignancies.
Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
[TBL] [Abstract][Full Text] [Related]
17. Management of adverse effects/toxicity of ibrutinib.
Paydas S
Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
[TBL] [Abstract][Full Text] [Related]
18. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
20. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
